Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population

Clinical and Experimental Rheumatology

Volumn 29, Issue 5, 2011, Pages 811-815

  Koga, T ^a   Okada, A ^a   Kawashiri, S ^a   Kita, J ^a   Suzuki, T ^a   Nakashima, Y ^a   Tamai, M ^a   Satoh, K ^a   Origuchi, T ^b   Iwamoto, N ^a   Yamasaki, S ^a   Nakamura, H ^a   Migita, K ^c   Ida, H ^d   Ueki, Y ^e   Eguchi, K ^a   Kawakami, A ^f  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Department of Medicine   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SASEBO CHUO HOSPITAL   (Japan)

Author keywords

Adalimumab; Primary failure; Rheumatoid arthritis; Urokinase plasminogen activator receptor

Indexed keywords

ADALIMUMAB; CHEMOKINE; CYTOKINE; MACROPHAGE MIGRATION INHIBITION FACTOR; UROKINASE RECEPTOR; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; DRUG MONITORING; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOLUBILITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83455173742     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N Engl J Med 2004; 350: 2167-79.
2. VAN DE PUTTE LB, ATKINS C, MALAISE M et al:. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16. (Pubitemid 38530193)
3. BARTELDS GM, WOLBINK GJ, STAPEL S et al.: High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006; 65: 1249-50. (Pubitemid 44277411)
4. SEKIGUCHI N, KAWAUCHI S, FURUYA T et al.: Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford). 2008; 47: 780-8. (Pubitemid 351796361)
5. SZEKANECZ Z, BESENYEI T, SZENTPETERY A, KOCH AE: Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 299-306.
6. SLOT O, BRUNNER N, LOCHT H, OXHOLM P, STEPHENS RW: Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ami Rheum Dis 1999; 58: 488-92. (Pubitemid 29359493)
7. MAY AE, SCHMIDT R, KANSE SM et al.: Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002; 100: 3611-7. (Pubitemid 35303930)
8. MIZUKAMI IF, FAULKNER NE, GYETKO MR, SITRIN RG, TODD 3RD RF: Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995; 86: 203-11.
9. PREVOO ML, VAN'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
10. VAN GESTEL AM, ANDERSON JJ, VAN RIEL PL et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999; 26: 705-11. (Pubitemid 29125596)
11. PALEOLOG EM, YOUNG S, STARK AC, MCCLOSKEY RV.FELDMANN M.MAINI R: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258-65. (Pubitemid 28313429)
12. KIM HR, PARK MK, CHO ML et al:. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 2007; 34: 927-36.
13. PARK JS, PARK JH, KHOI PN, JOO YE, JUNG YD: MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-{kappa}B signals in gastric cancer cells. Carcinogenesis 2011; 32: 175-81.
14. ASAHARA H, FUJISAWA K, KOBATA T et al.: Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997; 40: 912-8. (Pubitemid 27200009)
15. SIMMONDS RE, FOXWELL BM: Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47: 584-90. (Pubitemid 351619194)
16. KILLEENSD, ANDREWS EJ, WANG JH et al.: Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases. Br J Cancer 2007; 96: 262-8. (Pubitemid 46160631)
17. CLAVELG, BESSIS N, LEMEITER D et al:. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007; 124: 158-64. (Pubitemid 47059038)